OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors

Oncogene

Volumn 36, Issue 14, 2017, Pages 1911-1924

  Jung, L A ^a,b   Gebhardt, A ^a   Koelmel, W ^b   Ade, C P ^a   Walz, S ^c   Kuper, J ^b   Von Eyss, B ^a   Letschert, S ^d   Redel, C ^a   D'Artista, L ^e   Biankin, A ^f,g,h   Zender, L ^e   Sauer, M ^d   Wolf, E ^a   Evan, G ⁱ   Kisker, C ^b   Eilers, M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c University of Tübingen ^*  (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g GLASGOW ROYAL INFIRMARY   (United Kingdom)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARAGINE; CYSTEINE; DNA; DOXYCYCLINE; GLUTAMIC ACID; GLUTAMINE; HETERODIMER; HISTIDINE; HOMODIMER; LEUCINE; MAX PROTEIN; MYC PROTEIN; OLIGONUCLEOTIDE; OMOMYC PROTEIN; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BINDING SITE; CHROMATIN; CLINICAL EFFECTIVENESS; CRYSTAL STRUCTURE; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; MULTIPLE CANCER; ONCOGENE MYC; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN STRUCTURE; TUMOR INVASION; TUMOR REGRESSION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DOMINANT GENE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR MODEL; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; SEQUENCE HOMOLOGY;

BINDING SITES; CELLS, CULTURED; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PEPTIDE FRAGMENTS; PROMOTER REGIONS, GENETIC; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-MYC; SEQUENCE HOMOLOGY; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84991728056     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.354     Document Type: Article

References (51)

1. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
2. Kress TR, Sabo A, Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer 2015; 15: 593-607.
3. Wolf E, Lin CY, Eilers M, Levens DL. Taming of the beast: shaping Myc-dependent amplification. Trends Cell Biol 2015; 25: 241-248.
4. Shen-Li H, O'Hagan RC, Hou Jr H, Horner JW 2nd, Lee HW, DePinho RA. Essential role for Max in early embryonic growth and development. Genes Dev 2000; 14: 17-22.
5. Scognamiglio R, Cabezas-Wallscheid N, Thier MC, Altamura S, Reyes A, Prendergast AM et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 2016; 164: 668-680.
6. Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 2008; 3: 611-624.
7. Sabo A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 2014; 511: 488-492.
8. Kress TR, Cannell IG, Brenkman AB, Samans B, Gaestel M, Roepman P et al. The MK5/PRAK kinase and Myc form a negative feedback loop that is disrupted during colorectal tumorigenesis. Mol Cell 2011; 41: 445-457.
9. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev 2011; 25: 907-916.
10. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin- 1 to reverse the angiogenic switch. Proc Natl Acad Sci USA 2006; 103: 16266-16271.
11. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51-56.
12. Reimann M, Lee S, Loddenkemper C, Dörr JR, Tabor V, Aichele P et al. Tumor stroma-derived TGF-β limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 2010; 17: 262-272.
13. van Riggelen J, Muller J, Otto T, Beuger V, Yetil A, Choi PS et al. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 2010; 24: 1281-1294.
14. Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 2015; 526: 131-135.
15. Truitt ML, Conn CS, Shi Z, Pang X, Tokuyasu T, Coady AM et al. Differential requirements for eIF4E dose in normal development and cancer. Cell 2015; 162: 59-71.
16. Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008; 456: 971-975.
17. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455: 679-683.
18. Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat Commun 2014; 5: 4632.
19. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 2013; 27: 504-513.
20. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 1998; 17: 2463-2472.
21. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 2003; 112: 193-205.
22. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol 2007; 372: 774-797.
23. Abate C, Patel L, Rauscher FJ 3rd, Curran T. Redox regulation of fos and jun DNAbinding activity in vitro. Science 1990; 249: 1157-1161.
24. Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 2014; 511: 483-487.
25. Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, Evan GI et al. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One 2011; 6: e22284.
26. Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall'Olio V et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 2006; 8: 764-770.
27. Guo J, Li T, Schipper J, Nilson KA, Fordjour FK, Cooper JJ et al. Sequence specificity incompletely defines the genome-wide occupancy of Myc. Genome Biol 2014; 15: 482.
28. Lorenzin F, Benary U, Baluapuri A, Walz S, Jung LA, von Eyss B et al. Different promoter affinities account for specificity in MYC-dependent gene regulation. Elife; e-pub ahead of print 27 July 2016; doi:10.7554/eLife.15161.
29. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012; 151: 56-67.
30. Killian A, Sarafan-Vasseur N, Sesboue R, Le Pessot F, Blanchard F, Lamy A et al. Contribution of the BOP1 gene, located on 8q24, to colorectal tumorigenesis. Genes Chromosomes Cancer 2006; 45: 874-881.
31. Chung KY, Cheng IK, Ching AK, Chu JH, Lai PB, Wong N. Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition. Hepatology 2011; 54: 307-318.
32. Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T et al. A bisbenzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell 2013; 24: 791-805.
33. Fang HY, Chang CL, Hsu SH, Huang CY, Chiang SF, Chiou SH et al. ATPase family AAA domain-containing 3 A is a novel anti-apoptotic factor in lung adenocarcinoma cells. J Cell Sci 2010; 123: 1171-1180.
34. Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 2012; 22: 51-65.
35. Gilquin B, Taillebourg E, Cherradi N, Hubstenberger A, Gay O, Merle N et al. The AAA+ ATPase ATAD3A controls mitochondrial dynamics at the interface of the inner and outer membranes. Mol Cell Biol 2010; 30: 1984-1996.
36. Hoffmann M, Bellance N, Rossignol R, Koopman WJ, Willems PH, Mayatepek E et al. C. elegans ATAD-3 is essential for mitochondrial activity and development. PLoS One 2009; 4: e7644.
37. von Eyss B, Jaenicke LA, Kortlever RM, Royla N, Wiese KE, Letschert S et al. A Mycdriven change in mitochondrial dynamics limits YAP/TAZ function in mammary epithelial cells and breast cancer. Cancer Cell 2015; 28: 743-757.
38. Ferré D'Amaré AR, Prendergast GC, Ziff EB, Burley SK. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature 1993; 363: 38-45.
39. Thomas LR, Wang Q, Grieb BC, Phan J, Foshage AM, Sun Q et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol Cell 2015; 58: 440-452.
40. Jaenicke LA, von Eyss B, Carstensen A, Wolf E, Xu W, Greifenberg AK et al. Ubiquitin-dependent turnover of MYC antagonizes MYC/PAF1C complex accumulation to drive transcriptional elongation. Mol Cell 2016; 61: 54-67.
41. Rohrmoser M, Holzel M, Grimm T, Malamoussi A, Harasim T, Orban M et al. Interdependence of Pes1, Bop1, and WDR12 controls nucleolar localization and assembly of the PeBoW complex required for maturation of the 60 S ribosomal subunit. Mol Cell Biol 2007; 27: 3682-3694.
42. Husnjak K, Elsasser S, Zhang N, Chen X, Randles L, Shi Y et al. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 2008; 453: 481-488.
43. Chiang SF, Huang CY, Lin TY, Chiou SH, Chow KC. An alternative import pathway of AIF to the mitochondria. Int J Mol Med 2012; 29: 365-372.
44. Ruggero D. Translational control in cancer etiology. Cold Spring Harb Persp Biol 2013; 5: a012336.
45. Huang KH, Chow KC, Chang HW, Lin TY, Lee MC. ATPase family AAA domain containing 3 A is an anti-apoptotic factor and a secretion regulator of PSA in prostate cancer. Int J Mol Med 2011; 28: 9-15.
46. Liu YC, Li F, Handler J, Huang CR, Xiang Y, Neretti N et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One 2008; 3: e2722.
47. Cunningham JT, Moreno MV, Lodi A, Ronen SM, Ruggero D. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell 2014; 157: 1088-1103.
48. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. Sequence-specific DNA binding by the c-myc protein. Science 1990; 250: 1149-1151.
49. Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 2013; 5: 1704-1713.
50. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
51. Perna D, Faga G, Verrecchia A, Gorski MM, Barozzi I, Narang V et al. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene 2012; 31: 1695-1709.